HN2010001395A - Inhibidores de beta-lactamasa - Google Patents

Inhibidores de beta-lactamasa

Info

Publication number
HN2010001395A
HN2010001395A HN2010001395A HN2010001395A HN2010001395A HN 2010001395 A HN2010001395 A HN 2010001395A HN 2010001395 A HN2010001395 A HN 2010001395A HN 2010001395 A HN2010001395 A HN 2010001395A HN 2010001395 A HN2010001395 A HN 2010001395A
Authority
HN
Honduras
Prior art keywords
inhibitors
beta
lactamasa
lactama
antibiotics
Prior art date
Application number
HN2010001395A
Other languages
English (en)
Inventor
A Blizzard Timothy
Chen Helen
D Hermes Jeffrey
E Imbriglio Jason
Kim Seongkon
Y Wu Jane
Ha Sookhee
J Mortko Christopher
Mangion Ian
Rivera Nelo
T Ruck Rebecca
Shevlin Michael
Gude Candido
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of HN2010001395A publication Critical patent/HN2010001395A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/78—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Abstract

LA PRESENTE INVENCION SE REFIERE A LAS BETA LACTAMAS BICICLICAS SUSTITUIDAS DE FORMULA I:(I), SON INHIBIDORES DE B- LACTAMASA, EN LA QUE X,R1 Y R2SE DEFINEN EN EL PRESENTE DOCUMENTO. LOS COMPUESTOS Y SALES FARMACEUTICAMENTE ACEPTABLES DE LOS MISMOS SON UTILES EN EL TRATAMIENTO DE INFECCIONES BACTERIANAS JUNTO CON ANTIBIOTICOS DE B- LACTAMA. EN PARTICULAR, LOS COMPUESTOS PUEDEN EMPLEARSE CON UN ANTIBIOTICO DE B-LACTAMAS (POR EJEMPLO, IMIPENEM, PIPERACILINA O O CEFTAZIDINA) CONTRA MICROORGANISMOS RESISTENTES A ANTIBIOTICOS DE B- LACTAMA DEBIDO A LA PRESENCIA DE LAS B-LACTAMASAS.
HN2010001395A 2008-01-18 2010-07-12 Inhibidores de beta-lactamasa HN2010001395A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1153308P 2008-01-18 2008-01-18

Publications (1)

Publication Number Publication Date
HN2010001395A true HN2010001395A (es) 2012-11-12

Family

ID=40642204

Family Applications (1)

Application Number Title Priority Date Filing Date
HN2010001395A HN2010001395A (es) 2008-01-18 2010-07-12 Inhibidores de beta-lactamasa

Country Status (39)

Country Link
US (2) US8487093B2 (es)
EP (2) EP2231667B1 (es)
JP (3) JP5038509B2 (es)
KR (2) KR101800610B1 (es)
CN (2) CN101918407B (es)
AU (1) AU2009206119C1 (es)
BR (1) BRPI0906871B1 (es)
CA (1) CA2712783C (es)
CO (1) CO6331438A2 (es)
CR (1) CR11626A (es)
CY (5) CY1114900T1 (es)
DK (2) DK2231667T3 (es)
DO (1) DOP2010000218A (es)
EC (2) ECSP10010345A (es)
ES (2) ES2433744T3 (es)
FR (3) FR20C1031I2 (es)
HK (2) HK1143809A1 (es)
HN (1) HN2010001395A (es)
HR (2) HRP20131123T1 (es)
HU (2) HUS000504I2 (es)
IL (1) IL206395A (es)
LT (3) LTPA2020517I1 (es)
LU (1) LUC00165I2 (es)
MA (1) MA32025B1 (es)
ME (1) ME02089B (es)
MX (1) MX2010007823A (es)
MY (1) MY162532A (es)
NI (1) NI201000115A (es)
NL (2) NL301051I2 (es)
NO (1) NO2020024I1 (es)
NZ (1) NZ586861A (es)
PL (2) PL2666774T3 (es)
PT (2) PT2231667E (es)
RS (2) RS53862B1 (es)
RU (1) RU2445314C9 (es)
SI (2) SI2666774T1 (es)
UA (1) UA101966C2 (es)
WO (1) WO2009091856A2 (es)
ZA (1) ZA201005333B (es)

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS53862B1 (en) * 2008-01-18 2015-08-31 Merck Sharp & Dohme Corp. INHIBITOR BETA-LACTAMASE
PT2603514T (pt) 2010-08-10 2018-11-09 Rempex Pharmaceuticals Inc Derivados cíclicos de éster de ácido borónico e suas utilizações terapêuticas
US8772490B2 (en) 2010-12-22 2014-07-08 Meiji Seika Pharma Co., Ltd. Optically active diazabicyclooctane derivatives and process for preparing the same
CA2822758C (en) * 2010-12-22 2018-03-20 Meiji Seika Pharma Co., Ltd. Optically active diazabicyclooctane derivative and process for preparing the same
CA2780403C (en) * 2011-06-17 2020-04-21 Forest Laboratories Holdings Ltd. Processes for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof
MX348974B (es) * 2011-08-27 2017-07-04 Wockhardt Ltd Derivados 1,6 - diazabiciclo [3,2,1] octan-7-ona y su uso en el tratamiento de infecciones bacterianas.
RU2570423C2 (ru) 2011-08-30 2015-12-10 Вокхардт Лимитед Производные 1,6-диазабицикло[3.2.1]октан-7-она и их применение при лечении бактериальных инфекций
WO2013033461A1 (en) 2011-08-31 2013-03-07 Rempex Pharmaceuticals, Inc. Heterocyclic boronic acid ester derivatives and therapeutic uses thereof
US9505761B2 (en) 2011-12-02 2016-11-29 Fedora Pharmaceuticals Inc. Bicyclic compounds and their use as antibacterial agents and beta-lactamase inhibitors
US8796257B2 (en) 2011-12-02 2014-08-05 Naeja Pharmaceutical Inc. Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors
BR112014016804A8 (pt) 2012-01-06 2017-07-04 Univ California composições, métodos de uso e métodos de tratamento
US8916709B2 (en) 2012-03-30 2014-12-23 Cubist Pharmaceuticals, Inc. 1,2,4-oxadiazole and 1,2,4-thiadiazole β-lactamase inhibitors
MX2014011825A (es) * 2012-03-30 2015-02-20 Cubist Pharm Inc INHIBIDORES DE ISOXAZOL ß-LACTAMASA.
CA2868553A1 (en) * 2012-03-30 2013-10-03 Cubist Pharmaceuticals, Inc. 1,3,4-oxadiazole and 1,3,4-thiadiazole .beta.-lactamase inhibitors
US8969570B2 (en) 2012-03-30 2015-03-03 Cubist Pharmaceuticals, Inc. Beta-lactamase inhibitors
AR090539A1 (es) * 2012-04-02 2014-11-19 Astrazeneca Ab COMPUESTOS INHIBIDORES DE b LACTAMASA
EP2847327B1 (en) 2012-05-08 2018-12-26 Codexis, Inc. Biocatalysts and methods for hydroxylation of chemical compounds
US9156858B2 (en) 2012-05-23 2015-10-13 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
BR112014029368B1 (pt) * 2012-05-30 2020-10-27 Meiji Seika Pharma Co., Ltd inibidor de beta-lactamase e processo para preparar o mesmo
US10561675B2 (en) 2012-06-06 2020-02-18 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
BR112015003592B1 (pt) * 2012-08-25 2020-04-14 Wockhardt Ltd derivados de 1,6-diazabiciclo[3,2,1]octan-7-ona e seu uso no tratamento de infecções bacterianas
EP2915805A4 (en) * 2012-11-01 2016-03-23 Kaneka Corp METHOD FOR PRODUCING AN OPTICALLY ACTIVE BICYCLIC UREA COMPOUND
PT2928898T (pt) 2012-12-07 2021-07-05 Venatorx Pharmaceuticals Inc Inibidores de beta-lactamase
UA111925C2 (uk) * 2012-12-11 2016-06-24 Федора Фармасьютікалз Інк. БІЦИКЛІЧНІ СПОЛУКИ ТА ЇХ ВИКОРИСТАННЯ ЯК АНТИБАКТЕРІАЛЬНИХ АГЕНТІВ ТА ІНГІБІТОРІВ β-ЛАКТАМАЗИ
US9241947B2 (en) 2013-01-04 2016-01-26 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
CA2894892A1 (en) 2013-01-04 2014-07-10 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
CA2894891A1 (en) 2013-01-04 2014-07-10 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US9101638B2 (en) 2013-01-04 2015-08-11 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
EP2943204B1 (en) 2013-01-10 2019-03-13 Venatorx Pharmaceuticals Inc Beta-lactamase inhibitors
JP6285969B2 (ja) * 2013-03-08 2018-02-28 ウォックハート リミテッド （２ｓ，５ｒ）−７−オキソ−６−スルホオキシ−２−［（（３ｒ）−ピペリジン−３−カルボニル）−ヒドラジノカルボニル］−１，６−ジアザ−ビシクロ［３．２．１］オクタンの調製のためのプロセス
AU2013380573B2 (en) * 2013-03-08 2016-07-07 Wockhardt Limited A process for sodium salt of (2S, 5R)-2-carboxamido-7-oxo-6-sulfooxy -1,6-diaza-bicyclo[3.2.1]octane
KR101774132B1 (ko) 2013-03-08 2017-09-01 욱크하르트 리미티드 (2s, 5r)-7-옥소-6-술포옥시-2-[((3r)-피페리딘-3-카보닐)-히드라지노 카보닐]-1,6-디아자-비사이클로[3.2.1]-옥탄의 제조 방법
AU2013380575B2 (en) * 2013-03-08 2016-07-07 Wockhardt Limited A process for preparation of (2S, 5R)-7-oxo-6-sulphooxy-2-[((3R)-pyrrolidine-3-carbonyl)-hydrazino carbonyl]-1,6-diaza-bicyclo[3.2.1]octane
RU2621051C2 (ru) * 2013-03-08 2017-05-31 Вокхардт Лимитед Способ получения (2s, 5r)-моно-{ [(4-аминопиперидин-4-ил)карбонил]-7-оксо-1, 6-диазабицикло[3.2.1]окт-6-ил} ового сложного эфира серной кислоты
WO2014135931A1 (en) * 2013-03-08 2014-09-12 Wockhardt Limited A process for preparation of (2s, 5r)-7-oxo-6-sulphooxy-2-[((3r)-piperidine-3-carbonyl)-hydrazino carbonyl]-1,6-diaza-bicyclo [3.2.1]- octane
WO2014152996A1 (en) * 2013-03-14 2014-09-25 Cubist Pharmaceuticals, Inc. Crystalline form of a beta-lactamase inhibitor
WO2014151958A1 (en) 2013-03-14 2014-09-25 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
KR102265772B1 (ko) * 2013-06-10 2021-06-15 머크 샤프 앤드 돔 코포레이션 tert-부틸 4-((1R,2S,5R)-6-(벤질옥시)-7-옥소-1,6-디아자비시클로[3.2.1]옥탄-2-카르복스아미도)피페리딘-1-카르복실레이트의 제조
MY176278A (en) 2013-09-24 2020-07-27 Meiji Seika Pharma Co Ltd Process for producing diazabicyclooctane derivative and intermediate thereof
WO2015051101A1 (en) * 2013-10-02 2015-04-09 Cubist Pharmaceuticals, Inc. B-lactamase inhibitor picoline salt
EP3299370B1 (en) * 2013-10-08 2021-11-24 Meiji Seika Pharma Co., Ltd. Crystalline forms of diazabicyclooctane derivative and production process thereof
WO2015079329A2 (en) * 2013-11-26 2015-06-04 Wockhardt Limited A process for preparation of (2s, 5r)-7-oxo-n-[(2s)-pyrrolidin-2-yl-methyloxy]-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
PE20161371A1 (es) 2014-03-24 2016-12-21 Novartis Ag Compuestos organicos de monobactam para el tratamiento de infecciones bacterianas
IN2014MU01196A (es) * 2014-03-29 2015-10-02 Wockhardt Ltd
WO2015150891A1 (en) * 2014-03-29 2015-10-08 Wockhardt Limited A process for preparation of trans-sulfuric acid mono-[2-(5-azetidin-3-ylmethyl-[1,3,4]oxadiazol-2-yl)-7-oxo-1,6-diazabicyclo [3.2.1]oct-6-yl]ester
DK3140310T3 (da) 2014-05-05 2019-10-21 Rempex Pharmaceuticals Inc Syntese af boronatsalte og brug deraf
US9687497B1 (en) 2014-05-05 2017-06-27 Rempex Pharmaceuticals, Inc. Salts and polymorphs of cyclic boronic acid ester derivatives and therapeutic uses thereof
CA2947041A1 (en) 2014-05-19 2015-11-26 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
EP3882252A1 (en) 2014-06-11 2021-09-22 Venatorx Pharmaceuticals, Inc. Beta-lactamase inhibitors
US9511142B2 (en) 2014-06-11 2016-12-06 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
EP3164406A4 (en) 2014-07-01 2018-04-04 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
HUE044061T2 (hu) * 2014-11-17 2019-09-30 Entasis Therapeutics Ltd Kombinációs terápia rezisztens bakteriális fertõzések kezelésére
WO2016081297A1 (en) 2014-11-18 2016-05-26 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
CN107428784B (zh) 2014-12-02 2020-08-21 默沙东公司 用于制备4-((2s,5r)-6-(苄基氧基)-7-氧代-1,6-二氮杂双环[3.2.1]辛烷-2-甲酰胺基)哌啶-1-甲酸叔丁酯及其类似物的方法
WO2016088863A1 (ja) 2014-12-05 2016-06-09 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 ジアザビシクロオクタン誘導体の結晶及び安定な凍結乾燥製剤の製造法
US20180051041A1 (en) 2015-03-17 2018-02-22 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
TW201639853A (zh) * 2015-03-31 2016-11-16 木塔比利斯公司 雜環化合物及其於預防或治療細菌感染之用途
CN107580595B (zh) * 2015-05-07 2020-09-18 拜欧蒂姆公司 杂环化合物及它们在预防或治疗细菌感染中的应用
EP3347008B1 (en) 2015-09-11 2022-03-09 Venatorx Pharmaceuticals, Inc. Beta-lactamase inhibitors
MX2017013792A (es) * 2015-09-16 2018-07-06 Xuanzhu Pharma Co Ltd INHIBIDORES DE íŸ-LACTAMASA Y USOS DE LOS MISMOS.
EA201890847A1 (ru) 2015-10-02 2018-08-31 Легокем Байосайенсез, Инк. Композиции и способы ингибирования бета-лактамазы
WO2017100537A1 (en) 2015-12-10 2017-06-15 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
KR20180094042A (ko) * 2015-12-11 2018-08-22 욱크하르트 리미티드 7-옥소-6-(설포옥시)-1,6-디아자바이사이클로[3.2.1]옥탄-2-카르복사미드 함유 화합물 및 이의 세균 감염의 치료 용도
US10472345B2 (en) 2016-02-04 2019-11-12 Merck Sharp & Dohme Corp. Methods of preparing hydroxylamine derivatives useful in the preparation of anti-infective agents
TW201736370A (zh) * 2016-03-31 2017-10-16 Xuanzhu Pharma Co Ltd 一種抗菌組合物及其用途
EP3469088B1 (en) 2016-06-09 2023-09-06 Codexis, Inc. Biocatalysts and methods for hydroxylation of chemical compounds
WO2018005662A1 (en) 2016-06-30 2018-01-04 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
WO2018027062A1 (en) 2016-08-04 2018-02-08 VenatoRx Pharmaceuticals, Inc. Boron-containing compounds
PL3512851T3 (pl) * 2016-09-16 2022-11-14 Entasis Therapeutics Limited Związki stanowiące inhibitory beta-laktamazy
US10464937B2 (en) * 2016-09-19 2019-11-05 Merck Sharp & Dohme Corp. Process for preparing beta-lactamase inhibitor hydroxylurea intermediates
JOP20190061A1 (ar) * 2016-09-28 2019-03-26 Novartis Ag مثبطات بيتا-لاكتاماز
CN108078982B (zh) * 2016-11-21 2020-02-07 天津大学 脯氨酸衍生物在制备β-内酰胺酶抑制剂中的用途
CN117398398A (zh) 2017-03-06 2024-01-16 云顶新耀新加坡有限公司 包含β-内酰胺酶抑制剂的固体形式和组合式组合物及其用途
CN108619141B (zh) * 2017-03-16 2021-09-10 山东轩竹医药科技有限公司 一种抗菌组合物及其用途
EA038393B1 (ru) 2017-05-08 2021-08-20 Энтасис Терапеутикс, Инк. Соединения и способы для лечения бактериальных инфекций
US10085999B1 (en) 2017-05-10 2018-10-02 Arixa Pharmaceuticals, Inc. Beta-lactamase inhibitors and uses thereof
WO2018218154A1 (en) 2017-05-26 2018-11-29 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
US11332485B2 (en) 2017-05-26 2022-05-17 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
AU2018304907B2 (en) 2017-07-21 2022-11-24 Antabio Sas Chemical compounds
CN109568323B (zh) * 2017-09-29 2022-09-30 吉林四环制药有限公司 抗菌组合物及其用途
WO2019075084A1 (en) 2017-10-11 2019-04-18 Qpex Biopharma, Inc. BORONIC ACID DERIVATIVES AND SYNTHESIS THEREOF
WO2019105479A1 (zh) 2017-12-01 2019-06-06 南京明德新药研发股份有限公司 一种β-内酰胺酶抑制剂的晶型及其制备方法
CN109956941B (zh) * 2017-12-25 2020-08-04 新发药业有限公司 一种阿维巴坦的简便制备方法
EP3744722A4 (en) 2018-01-25 2021-11-03 Suzhou Sinovent Pharmaceuticals Co., Ltd. Ss-LACTAMASE INHIBITOR AND ITS USE
EP3572411A1 (en) 2018-05-21 2019-11-27 Antabio SAS Thiazole derivatives as metallo-beta-lactamase inhibitors
WO2020030761A1 (en) * 2018-08-09 2020-02-13 Antabio Sas Diazabicyclooctanones as inhibitors of serine beta-lactamases
US11905286B2 (en) 2018-08-09 2024-02-20 Antabio Sas Diazabicyclooctanones as inhibitors of serine beta-lactamases
EP3670512A1 (en) * 2018-12-18 2020-06-24 Antabio SAS Diazabicyclooctanones as inhibitors of serine beta-lactamases
US11897844B2 (en) 2018-09-21 2024-02-13 Api Corporation Method for producing amino acid derivatives
CA3114618C (en) * 2018-10-01 2023-09-05 Arixa Pharmaceuticals, Inc. Derivatives of relebactam and uses thereof
CN111072660B (zh) * 2018-10-22 2021-05-18 新发药业有限公司 一种瑞来巴坦的简便制备方法
SG11202108905UA (en) 2019-03-12 2021-09-29 Arixa Pharmaceuticals Inc Crystalline form of an avibactam derivative
WO2020219405A1 (en) * 2019-04-26 2020-10-29 Merck Sharp & Dohme Corp. Process for the preparation of intermediates useful for making (2s,5r)-7-oxo-n-piperidin-4-yl-6-(sulfoxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
WO2022047790A1 (en) * 2020-09-07 2022-03-10 Ningxia Academy Of Agriculture And Forestry Sciences Amidine substituted bicyclic compounds, their preparation, their use as antibacterial agents and beta-lactamase inhibitors
CN111943950B (zh) * 2020-09-10 2022-03-29 山东安信制药有限公司 一种瑞来巴坦的制备方法
US11814385B2 (en) * 2021-06-25 2023-11-14 University Of South Florida Small molecule inhibitors targeting Clostridioides difficile sporulation
WO2023220324A1 (en) * 2022-05-11 2023-11-16 The Regents Of The University Of Colorado A Body Corporate Antibiotic composition and methods of use thereof

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4616038A (en) 1978-07-24 1986-10-07 Merck & Co., Inc. Combination of thienamycin-type antibiotics with dipeptidase inhibitors
US5071843A (en) 1978-07-24 1991-12-10 Merck & Co., Inc. Combination of 2-substituted carbapenems with dipeptidase inhibitors
US4880793A (en) 1978-07-24 1989-11-14 Merck & Co., Inc. Combination of thienamycin-type antibiotics with dipeptidase inhibitors
US4539208A (en) 1980-09-17 1985-09-03 Merck & Co., Inc. Combination of thienamycin-type antibiotics with dipeptidase inhibitors
EP0508234B1 (de) 1991-04-11 1996-07-24 F. Hoffmann-La Roche Ag Beta-Lactame
US5854239A (en) 1993-12-29 1998-12-29 Pfizer Inc. Diazabicyclic neuokinin antagonists
JP3199300B2 (ja) 1994-05-09 2001-08-13 三共株式会社 １−メチルカルバペネム誘導体
CA2241092C (en) 1995-12-21 2004-04-27 Sankyo Company, Limited 1-methylcarbapenem derivatives
JP2965922B2 (ja) * 1995-12-21 1999-10-18 三共株式会社 １−メチルカルバペネム誘導体
JP2955276B2 (ja) 1997-06-19 1999-10-04 三共株式会社 １−メチルカルバペネム誘導体を含有する抗菌剤
JP4490517B2 (ja) 1998-03-19 2010-06-30 富山化学工業株式会社 ５−デオキシ−５−アルカノイルアミノ−β−Ｄ−アロフラノシルウロン酸誘導体またはその塩、それらを含有する抗真菌剤及びキチン合成酵素阻害剤
EP1194436B1 (en) 1999-07-06 2005-11-30 Methylgene, Inc. Sulfonamidomethyl phosphonate inhibitors of beta-lactamase
MXPA02001394A (es) * 1999-08-10 2002-08-12 British Biotech Pharm Agentes antibacterianos.
FR2812635B1 (fr) * 2000-08-01 2002-10-11 Aventis Pharma Sa Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens
CA2429346A1 (en) 2000-11-16 2002-05-23 Sankyo Company, Limited 1-methylcarbapenem derivatives
JP2002212182A (ja) * 2000-11-16 2002-07-31 Sankyo Co Ltd １−メチルカルバペネム誘導体
FR2825705B1 (fr) 2001-06-08 2005-05-20 Aventis Pharma Sa Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens
FR2835186B1 (fr) * 2002-01-28 2006-10-20 Aventis Pharma Sa Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
JP2004043438A (ja) 2002-05-15 2004-02-12 Sankyo Co Ltd １−メチルカルバペネム誘導体を含有する医薬
US7439253B2 (en) 2002-12-06 2008-10-21 Novexel Heterocyclic compounds, their preparation and their use as medicaments, in particular as antibacterials and beta-lactamase inhibitors
CA2531728A1 (en) * 2003-07-09 2005-02-03 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds
US6984652B2 (en) 2003-09-05 2006-01-10 Warner-Lambert Company Llc Gyrase inhibitors
WO2005033129A1 (de) 2003-10-01 2005-04-14 Bayer Healthcare Ag Antibakterielle amid-makrozyklen
EP1751527A2 (en) 2004-02-24 2007-02-14 SSCI, Inc. Analysis and screening of solid forms using the atomic pair distribution function
KR101403164B1 (ko) * 2005-12-07 2014-06-03 바실리어 파마슈티카 아게 베타-락타마아제 저해제 및 모노박탐 항생물질의 유용한조합
AU2007300531A1 (en) 2006-09-27 2008-04-03 Merck Sharp & Dohme Corp. Novel inhibitors of beta-lactamase
RS53862B1 (en) * 2008-01-18 2015-08-31 Merck Sharp & Dohme Corp. INHIBITOR BETA-LACTAMASE

Also Published As

Publication number Publication date
EP2231667A2 (en) 2010-09-29
KR20100130176A (ko) 2010-12-10
SI2666774T1 (sl) 2015-04-30
LUC00165I2 (es) 2021-08-16
CA2712783A1 (en) 2009-07-23
FR20C1032I2 (fr) 2022-07-29
JP5038509B2 (ja) 2012-10-03
CA2712783C (en) 2013-03-19
WO2009091856A2 (en) 2009-07-23
DOP2010000218A (es) 2010-08-31
RU2445314C9 (ru) 2013-04-10
UA101966C2 (en) 2013-05-27
JP2011207900A (ja) 2011-10-20
CY1114900T1 (el) 2016-12-14
HK1186180A1 (en) 2014-03-07
IL206395A (en) 2015-04-30
CY2020024I2 (el) 2020-11-25
CY1116243T1 (el) 2017-03-15
DK2231667T3 (da) 2013-12-16
ZA201005333B (en) 2011-04-28
LTPA2020517I1 (lt) 2020-07-27
FR20C1031I2 (fr) 2022-07-29
MX2010007823A (es) 2010-08-10
CN101918407B (zh) 2014-02-26
IL206395A0 (en) 2010-12-30
SI2231667T1 (sl) 2013-12-31
CY2020025I1 (el) 2020-11-25
ES2533826T3 (es) 2015-04-15
NZ586861A (en) 2011-12-22
CR11626A (es) 2010-09-13
JP5422020B2 (ja) 2014-02-19
HUS2000023I1 (hu) 2021-03-29
MA32025B1 (fr) 2011-01-03
ECSP10010345A (es) 2010-08-31
DK2666774T3 (en) 2015-03-23
EP2231667B1 (en) 2013-09-04
EP2666774A1 (en) 2013-11-27
CY2020023I1 (el) 2020-11-25
AU2009206119B2 (en) 2012-06-07
NL301051I2 (nl) 2020-09-03
ME02089B (me) 2014-04-30
PT2231667E (pt) 2013-12-13
RS53862B1 (en) 2015-08-31
US20130274475A1 (en) 2013-10-17
HK1143809A1 (en) 2011-01-14
JP5597164B2 (ja) 2014-10-01
PT2666774E (pt) 2015-04-13
HUS2000024I1 (hu) 2021-03-29
RS53052B (en) 2014-04-30
FR20C1032I1 (es) 2020-02-10
AU2009206119C1 (en) 2016-05-26
PL2666774T3 (pl) 2015-06-30
HRP20150269T1 (hr) 2015-04-24
FR20C1031I1 (es) 2020-02-10
NI201000115A (es) 2011-07-08
HUS000513I2 (hu) 2021-03-29
NO2020024I1 (no) 2020-08-10
KR101800610B1 (ko) 2017-11-23
WO2009091856A3 (en) 2009-12-03
US20110294777A1 (en) 2011-12-01
CN102827067A (zh) 2012-12-19
CY2020023I2 (el) 2020-11-25
JP2011510012A (ja) 2011-03-31
US8487093B2 (en) 2013-07-16
FR20C1030I1 (fr) 2020-02-10
LTC2666774I2 (lt) 2022-01-25
CO6331438A2 (es) 2011-10-20
BRPI0906871B1 (pt) 2021-09-28
AU2009206119A1 (en) 2009-07-23
KR101648728B1 (ko) 2016-08-17
CN101918407A (zh) 2010-12-15
KR20160099117A (ko) 2016-08-19
CY2020024I1 (el) 2020-11-25
HUS000504I2 (hu) 2021-03-29
LTPA2020516I1 (lt) 2020-07-27
CN102827067B (zh) 2015-09-23
EP2666774B1 (en) 2015-01-07
PL2231667T3 (pl) 2014-01-31
LTC2231667I2 (lt) 2021-07-26
LTPA2020518I1 (lt) 2020-07-27
RU2445314C1 (ru) 2012-03-20
CY2020025I2 (el) 2020-11-25
HRP20131123T1 (hr) 2013-12-20
FR20C1030I2 (fr) 2021-08-27
ECSP10010568A (es) 2010-11-30
MY162532A (en) 2017-06-15
NL301050I2 (nl) 2020-09-03
JP2012214475A (ja) 2012-11-08
ES2433744T3 (es) 2013-12-12
BRPI0906871A2 (pt) 2020-07-28

Similar Documents

Publication Publication Date Title
HN2010001395A (es) Inhibidores de beta-lactamasa
ECSP18005828A (es) Inhibidores de metalo-beta-lactamasa
DOP2014000212A (es) Compuestos inhibidores de beta-lactamasas
AR124237A2 (es) NUEVO INHIBIDOR DE b-LACTAMASA Y PROCESO PARA PREPARARLO
CY1117934T1 (el) Αντιβακτηριακες φαρμακευτικες συνθεσεις
GT200800170A (es) Compuestos de n-formil-hidroxilamina
CU20110083A7 (es) Compuestos heteroaromáticos espirocíclicos fusionados para el tratamiento de infecciones bacterianas
CO6640246A2 (es) Forma cristalina del inhibidor sglt2 bencilbenceno
ECSP088676A (es) Pirazolquinolonas como potentes inhibidores de parp
CO6270305A2 (es) Derivados de {[(5-fluoro-4-pirimidinil)hidrazino]3-oxopropil} hidroxi formamida y sus composiciones, utiles cmo inhibidores de la actividad de la peptido de formilasa bacteriana (pdf)
CU20100035A7 (es) Derivados de ciclopropilamida como moduladores h3
GT200600235A (es) Penemes triciclicos de 6-alquilideno como inhibidores de beta-lactamasas clase d
UY30788A1 (es) Compuestos quimicos
NI201100035A (es) Agentes antifúngicos.
ECSP11011053A (es) [4-(1-amino-etil)-ciclohexil]-metil-aminas como antibacterianos
CO2019001995A2 (es) Inhibidores de beta-lactamasa
CR10998A (es) Macrolidos
UY32197A (es) Sinergismo antibiotico
MX2010014248A (es) Nuevos antibioticos de trinem e inhibidores de beta-lactamasas.
CL2009001493A1 (es) Compuestos derivados de 3-cianopirrolidin-fenil-oxazolidinonas; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de infecciones bacterianas.
GT200600477A (es) Inhibidores de integrasa de vih
UY30509A1 (es) Profarmacos antimicrobianos de oxazolidinona